Current Edition

news

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination ca...
Continue Reading →
news

Pegfilgrastim Biosimilar Matches Reference Product

Sandoz's biosimilar of Neulasta, or pegfilgrastim, matched the reference product in a clinical trial, according to the company. Researchers found equivalence in pharm...
Continue Reading →
news

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o...
Continue Reading →
news

JW Pharma releases cancer treatment trial results

South Korea based JW Pharmaceuticals recently presented phase 1a/1b clinical trial results for CWP291, a target anticancer treatment that uses Wnt signaling pathway, ...
Continue Reading →
news

GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-review...
Continue Reading →
news

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

 Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet pat...
Continue Reading →
news

SOTIO Broadens Its Phase II Clinical Trial Program in Ovarian Cancer

SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient to a Phase II study testing DCVAC/OvCa in combination with ...
Continue Reading →
news

New study results support use of DiviTum ® for evaluation of pancreatic cancer

In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer are published in the Pancreas scientific journal. The res...
Continue Reading →
news

Arcus Biosciences secures funding to advance clinical programs for AB928

Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m. The proceeds from ...
Continue Reading →
news

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data...
Continue Reading →